Corvus Pharmaceuticals, Inc.

Corvus Pharmaceuticals Misses on EPS, Stock Up 1.94%

Corvus Pharmaceuticals reported a loss of $0.73 per share for the second quarter of 2017. Despite the loss, the stock rose by 1.94%, indicating that investors may have had lower expectations or are optimistic about future developments. The lack of revenue data and management commentary leaves some uncertainty about the company's current position and future outlook.